Characteristics and outcomes for patients with TP53-mutated vs TP53-unmutated PTCL
| . | TP53 mutated (n = 21) . | TP53 unmutated (n = 111) . | P . |
|---|---|---|---|
| Median age, y (range) | 60 (46-79) | 66 (25-82) | .39 |
| Sex, n (%) | |||
| Male | 16 (76) | 65 (59) | .15 |
| Female | 5 (24) | 46 (41) | |
| Histology, n (% frequency per histology) | |||
| PTCL-NOS | 10/36 (28) | 26/36 (72) | .03 |
| AITL | 2/62 (3) | 60/62 (97) | < .001 |
| PTCL-TFH | 2/9 (22) | 7/9 (78) | .63 |
| ALK− ALCL | 5/15 (33) | 10/15 (67) | .06 |
| ALK+ ALCL | 1/6 (17) | 5/6 (83) | >.99 |
| MEITL | 1/4 (25) | 3/4 (75) | .50 |
| Stage, n (%) | |||
| I/II∗ | 5 (24) | 17 (15) | .35 |
| III/IV∗ | 16 (76) | 94 (85) | |
| BM involvement by (by morphological assessment), n (%) | |||
| N | 13 (62) | 59 (53) | .17 |
| Y | 3 (14) | 36 (32) | |
| Unconfirmed | 5 (24) | 16 (14) | |
| Other extranodal sites of involvement, n (%) | |||
| N | 12 (57) | 69 (62) | .81 |
| Y | 9 (43) | 42 (38) | |
| IPI score, n (%) | |||
| 0-1 | 2 (10) | 17 (15) | .80 |
| 2 | 5 (24) | 26 (23) | |
| 3 | 5 (24) | 25 (23) | |
| 4-5 | 1 (5) | 15 (14) | |
| Incomplete data | 8 (38) | 28 (25) | |
| PIT score, n (%) | |||
| 0-1 | 8 (38) | 36 (32) | .79 |
| 2 | 3 (14) | 21 (19) | |
| 3-4 | 2 (10) | 17 (15) | |
| Incomplete data | 8 (38) | 37 (33) | |
| First-line treatment, n (%) | |||
| CHOP | 4 (19) | 36 (32) | .16 |
| CHOEP/EPOCH | 11 (52) | 48 (43) | |
| BV-CH(E)P | 5 (24) | 11 (10) | |
| CHOP-based + novel agent | 1 (5) | 16 (14) | |
| Response to induction, n (%) | |||
| CR | 9 (43) | 73 (66) | .053 |
| <CR | 12 (57) | 38 (34) | |
| Received ASCT in first remission, n (%) | |||
| Y | 6 (29) | 44 (40) | .17 |
| N | 15 (71) | 67 (60) | |
| Outcomes after ASCT, n (%) | |||
| PFS event | 5/6 (83) | 29/44 (66) | .65 |
| Ongoing remission | 1/6 (17) | 15/44 (34) | |
| MSK-IMPACT sample sequencing time point, n (%) | |||
| Diagnostic biopsy | 10 (48) | 77 (69) | .09 |
| First relapse biopsy | 5 (24) | 20 (18) | |
| Beyond first relapse | 6 (29) | 14 (13) | |
| Other aberrancies, n (%) | |||
| TP53 or 17p deletion | 6 (29) | 3 (3) | <.001 |
| CDKN2A deletion or mutation | 3 (14) | 9 (8) | .41 |
| DNMT3A mutation | 2 (10) | 23 (21) | .36 |
| TET2 mutation | 6 (29) | 63 (57) | .03 |
| RHOA | 2 (10) | 38 (34) | .04 |
| IDH2 | 0 (0) | 15 (13) | .13 |
| Median number of aberrancies (range) | 11 (1-48) | 5 (0-33) | .008 |
| . | TP53 mutated (n = 21) . | TP53 unmutated (n = 111) . | P . |
|---|---|---|---|
| Median age, y (range) | 60 (46-79) | 66 (25-82) | .39 |
| Sex, n (%) | |||
| Male | 16 (76) | 65 (59) | .15 |
| Female | 5 (24) | 46 (41) | |
| Histology, n (% frequency per histology) | |||
| PTCL-NOS | 10/36 (28) | 26/36 (72) | .03 |
| AITL | 2/62 (3) | 60/62 (97) | < .001 |
| PTCL-TFH | 2/9 (22) | 7/9 (78) | .63 |
| ALK− ALCL | 5/15 (33) | 10/15 (67) | .06 |
| ALK+ ALCL | 1/6 (17) | 5/6 (83) | >.99 |
| MEITL | 1/4 (25) | 3/4 (75) | .50 |
| Stage, n (%) | |||
| I/II∗ | 5 (24) | 17 (15) | .35 |
| III/IV∗ | 16 (76) | 94 (85) | |
| BM involvement by (by morphological assessment), n (%) | |||
| N | 13 (62) | 59 (53) | .17 |
| Y | 3 (14) | 36 (32) | |
| Unconfirmed | 5 (24) | 16 (14) | |
| Other extranodal sites of involvement, n (%) | |||
| N | 12 (57) | 69 (62) | .81 |
| Y | 9 (43) | 42 (38) | |
| IPI score, n (%) | |||
| 0-1 | 2 (10) | 17 (15) | .80 |
| 2 | 5 (24) | 26 (23) | |
| 3 | 5 (24) | 25 (23) | |
| 4-5 | 1 (5) | 15 (14) | |
| Incomplete data | 8 (38) | 28 (25) | |
| PIT score, n (%) | |||
| 0-1 | 8 (38) | 36 (32) | .79 |
| 2 | 3 (14) | 21 (19) | |
| 3-4 | 2 (10) | 17 (15) | |
| Incomplete data | 8 (38) | 37 (33) | |
| First-line treatment, n (%) | |||
| CHOP | 4 (19) | 36 (32) | .16 |
| CHOEP/EPOCH | 11 (52) | 48 (43) | |
| BV-CH(E)P | 5 (24) | 11 (10) | |
| CHOP-based + novel agent | 1 (5) | 16 (14) | |
| Response to induction, n (%) | |||
| CR | 9 (43) | 73 (66) | .053 |
| <CR | 12 (57) | 38 (34) | |
| Received ASCT in first remission, n (%) | |||
| Y | 6 (29) | 44 (40) | .17 |
| N | 15 (71) | 67 (60) | |
| Outcomes after ASCT, n (%) | |||
| PFS event | 5/6 (83) | 29/44 (66) | .65 |
| Ongoing remission | 1/6 (17) | 15/44 (34) | |
| MSK-IMPACT sample sequencing time point, n (%) | |||
| Diagnostic biopsy | 10 (48) | 77 (69) | .09 |
| First relapse biopsy | 5 (24) | 20 (18) | |
| Beyond first relapse | 6 (29) | 14 (13) | |
| Other aberrancies, n (%) | |||
| TP53 or 17p deletion | 6 (29) | 3 (3) | <.001 |
| CDKN2A deletion or mutation | 3 (14) | 9 (8) | .41 |
| DNMT3A mutation | 2 (10) | 23 (21) | .36 |
| TET2 mutation | 6 (29) | 63 (57) | .03 |
| RHOA | 2 (10) | 38 (34) | .04 |
| IDH2 | 0 (0) | 15 (13) | .13 |
| Median number of aberrancies (range) | 11 (1-48) | 5 (0-33) | .008 |
BV-CH(E)P, CHOP with brentuximab vedotin in place of vincristine with or without etoposide; CHOEP, CHOP with etoposide; N, no; Y, yes.
Bold indicates P < .05.
One patient with documented stage II disease and 8 patients with documented stage III disease based on imaging were missing baseline BM biopsies.